Health
Affinity’s COVID-19 antibodies ready for manufacture for clinical trials – BSA bureau
The neutralizing antibodies under trial are potentially useful for vaccine development for an apid therapy or to protect people in high-risk situations such as healthcare workers or people in direct contact with COVID patients.
The neutralizing antibodies under trial are potentially useful for vaccine development for an apid therapy or to protect people in high-risk situations such as healthcare workers or people in direct contact with COVID patients.
Melbourne-based Affinity Biosciences Pty Ltd (Affinity) has lodged a pre-publication submission to the scientific journal, ‘mAbs’, detailing its results and observations relating to the discovery of potent antibodies against COVID-19. This can be found at the link,’Antib…
-
General24 hours agoAustralia’s Myanmar community mourns earthquake losses
-
Noosa News23 hours agoAustralian growers expect to benefit from US tariffs as Trump’s trade war angers markets
-
Noosa News20 hours agoDisaster relief packages announced for flood-stricken western Queensland
-
Noosa News23 hours agoHow to get the most from potted citrus and when they’ll fruit